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Background: In 2008, the Cochrane Collaboration introduced a tool for assessing the risk of bias in clinical trials
included in Cochrane reviews. The risk of bias (RoB) tool is based on narrative descriptions of evidence-based
methodological features known to increase the risk of bias in trials.
Methods: To assess the usability of this tool, we conducted an evaluation by means of focus groups, online surveys
and a face-to-face meeting. We obtained feedback from a range of stakeholders within The Cochrane Collaboration
regarding their experiences with, and perceptions of, the RoB tool and associated guidance materials. We then
assessed this feedback in a face-to-face meeting of experts and stakeholders and made recommendations for
improvements and further developments of the RoB tool.
Results: The survey attracted 380 responses. Respondents reported taking an average of between 10 and
60 minutes per study to complete their RoB assessments, which 83% deemed acceptable. Most respondents
(87% of authors and 95% of editorial staff) thought RoB assessments were an improvement over past approaches
to trial quality assessment. Most authors liked the standardized approach (81%) and the ability to provide quotes to
support judgements (74%). A third of participants disliked the increased workload and found the wording
describing RoB judgements confusing. The RoB domains reported to be the most difficult to assess were
incomplete outcome data and selective reporting of outcomes. Authors expressed the need for more guidance on
how to incorporate RoB assessments into meta-analyses and review conclusions. Based on this evaluation,
recommendations were made for improvements to the RoB tool and the associated guidance. The implementation
of these recommendations is currently underway.
Conclusions: Overall, respondents identified positive experiences and perceptions of the RoB tool. Revisions of the
tool and associated guidance made in response to this evaluation, and improved provision of training, may
improve implementation.
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Systematic reviews of randomized trials provide the best
evidence about the effects of healthcare interventions.
Nevertheless, randomized trials are not immune from
bias. There is good empirical evidence [1-3] that flaws in
particular aspects of trial conduct may lead to biased
intervention effect estimates, which will then bias results
of systematic reviews that aim to collate and synthesize
all studies meeting pre-specified eligibility criteria. It is
therefore important, in order to minimize bias in the
conclusions of a systematic review, to consider potential
limitations of each eligible study.
Systematic reviews produced by The Cochrane Collab-
oration have previously used a variety of methods to as-
sess methodological quality of included trials [4]. There
was no consistency between approaches recommended
by different Cochrane Review Groups, most of the ap-
proaches were not evidence-based and many review
groups used methods based on numerical scores, which
have been shown to be inadequate [4,5]. In 2005, The
Cochrane Collaboration’s Methods Groups initiated the
development of a new strategy for addressing the quality
of randomized trials. This project commenced with a
3-day meeting of statisticians, epidemiologists and re-
view authors, held in Cambridge, UK, following which
designated pairs of individuals wrote the first draft of
different components of the tool. In brief, the CochraneTable 1 The original risk of bias tool
Domain Description
Sequence generation Describe the method
sequence in sufficient
whether it should pro
Allocation concealment Describe the method
sequence in sufficient
intervention allocation
advance of, or during
Blinding of participants, personnel and outcome
assessors. Assessments should be made for each






Incomplete outcome data. Assessments should be








Selective outcome reporting State how the possibi
was examined by the
found
Other sources of bias State any important c




Based on Higgins and Altman [6]. The original tool was in use at the time focus grorisk of bias (RoB) tool involves assessment of the risk of
bias arising from each of six domains (generation of the
allocation sequence, concealment of the allocation se-
quence, blinding, incomplete outcome data, selective
outcome reporting and other biases). In contrast to pre-
vious approaches, this tool elicited judgements for the
domain-level risk of bias, supported by narrative explan-
ation of evidence-based methodological features known
to increase the risk of bias in trials. The narrative descrip-
tion can include quotes from the papers that authors have
used to inform their judgements. Another novel feature of
the tool was that figures can be generated to display the
RoB judgements graphically across included studies. The
original version of the RoB tool (Table 1) was first pub-
lished in 2008 in the Cochrane Handbook for Systematic
Reviews of Interventions [6] and implemented in the
Collaboration’s review-writing software, RevMan [7]. An
updated version was published in 2011 [8,9].
In this paper, we describe the results of an evaluation
of the initial version of The Cochrane Collaboration’s
RoB tool following its launch in 2008, the resulting rec-
ommendations for amendments and current progress in
their implementation. Objectives of the evaluation were
to: 1) assess the usability of the tool; 2) assess the accept-
ability of the resources needed to use the tool; 3) identify
areas authors are finding difficult to implement; and 4)
identify additional training requirements.Review authors’ judgement
used to generate the allocation
detail to allow an assessment of
duce comparable groups
Was the allocation sequence
adequately generated?
used to conceal the allocation
detail to determine whether




used, if any, to blind study
nnel from knowledge of which
ant received. Provide any
o whether the intended blinding
Was knowledge of the allocated
intervention adequately
prevented during the study?
eness of outcome data for each
ing attrition and exclusions from the
r attrition and exclusions were
s in each intervention group
randomized participants), reasons
s where reported, and any re-
performed by the review authors
Were incomplete outcome data
adequately addressed?
lity of selective outcome reporting
review authors, and what was
Are reports of the study free of
suggestion of selective outcome
reporting?
oncerns about bias not addressed in
the tool
Was the study apparently free of
other problems that could put it
at a high risk of bias?
/entries were pre-specified in the
onses should be provided for each
ups and survey were administered (September 2009 to February 2010).
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The evaluation of the RoB tool was initiated in early 2009.
A planning meeting, comprising the organizing committee
and other Cochrane contributors with relevant expertise
and/or experience, including editors and other editorial
office staff, was held during the 17th annual Cochrane
Colloquium in Singapore in October 2009. The evaluation
consisted of three stages.
First, a series of focus groups was held with a main
goal of guiding the development of a questionnaire that
would be subsequently used to survey stakeholders
within The Cochrane Collaboration. Participants were
invited to take part in focus groups via emails sent to a
Cochrane Collaboration mailing list (CC-Info) and the
focus groups were also listed in the program on the 17th
Cochrane Colloquium website. Four 90-minute focus
groups were held: one via teleconference and three in
person during the Colloquium. The discussions were
semi-structured and open-ended and were facilitated by
one team member (DM, JACS, JS or LW). Questions
focused on experiences with the RoB tool, perceptions
about the level of difficulty in using the tool and in sum-
marizing RoB assessments at different levels, confidence
in RoB assessments and perspectives regarding the suffi-
ciency and adequacy of available training materials, or
reasons for non-use of the tool. The discussions were
recorded and transcribed. Transcripts were coded using
basic content analysis to identify questionnaire items and
appropriate response categories.
Analysis of transcripts from the focus groups, together
with the expertise of investigators and project staff,
guided the development of three online questionnaires
aimed at: 1) review authors who had used the tool; 2)
review authors who had not used the tool (to ask about
barriers); and 3) editorial teams within the Collabor-
ation. Questionnaires were pilot tested before the survey
was launched. Review authors who had used the RoB
tool were asked questions assessing their experience of
using the tool, including workload, opinions and percep-
tions of the tool, experience with specific bias domains,
and training preferences (32 questions). Review authors
who had not used the RoB tool were asked about rea-
sons for not using the tool and about training prefer-
ences (nine questions). Review group staff were asked
about their experiences of providing support to review
authors (29 questions). Participants were recruited through
established Cochrane Collaboration mailing lists. Links to
each questionnaire were emailed to lists of review authors
(5,038 subscribers), coordinating editors (79 subscribers),
managing editors (69 subscribers) and to the general pur-
pose email list, CC-Info (2,182 subscribers). The survey
took place over a 3-week period in February 2010. The
extent of subscriber overlap between these lists was un-
known as they are maintained by different groups and areconfidential. In addition, it was not possible to estimate
the proportion of out-of-date or inactive subscribers in
each list. Responses were analyzed using descriptive statis-
tics, and free-text answers were analyzed by basic content
analysis.
A face-to-face meeting was held in Cardiff, UK, in
March 2010 to discuss results from the focus groups and
surveys, and consider revisions to the first version of the
RoB tool. There were 23 participants, including statisti-
cians, epidemiologists, Cochrane review authors, editors
and other members of Cochrane Review Groups and
Cochrane Methods Groups, and the Editor in Chief of
The Cochrane Library (http://www.thecochranelibrary.
com). At the meeting, results from the focus groups
and surveys were presented to initiate a semi-structured,
open-ended discussion regarding specific aspects of imple-
mentation, while encouraging participants to raise issues
they considered important. The discussion was guided
by a set of topic areas identified as important through
the survey. Recommendations for changes to the RoB
tool and related guidance in the Cochrane Handbook
were discussed and agreed through informal consensus.
In the months after the meeting, we collaborated with
relevant groups within The Cochrane Collaboration to
implement the proposed changes, including working
with the software developers to integrate the proposed
changes into Cochrane software and making arrange-
ments for revising relevant guidance. As a part of a wider
consultation within The Cochrane Collaboration about
the proposed changes, an interactive discussion workshop
was held at the 18th Cochrane Colloquium in Keystone,
CO, USA. This was open to any Colloquium participants
interested in attending. We presented the results from the
online surveys as well as the proposed recommendations
and invited participants to discuss the recommendations
and provide feedback. Discussion points and feedback
were recorded and fed back to the evaluation team and
other groups within the Collaboration involved in the im-
plementation of the recommendations. The implementa-
tion of proposed longer-term changes is ongoing and
working groups were set up with the aim of continuous
evaluation and development of the RoB tool.
This project was approved by the Ottawa Hospital
Research Institute Ethics Committee (ON, Canada). The
University of Bristol Faculty of Medicine and Dentistry
Ethics Committee (Bristol, UK) classified this project as
an audit of research practices, rather than a research




The four focus groups involved 25 participants, the major-
ity of whom were experienced users of the RoB tool.
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used it in the context of a Cochrane review. The main
topics of discussion were: how the RoB tool is used in
practice (for example pilot testing, updated reviews, modi-
fications, use of quotes); opinions of the RoB tool (for ex-
ample comparison to past practice, aspects liked and not
liked); opinions of, and experiences with, specific domains;
and current and desired training materials.
Focus group participants felt that the RoB tool was an
improvement over past practice. Specific benefits de-
scribed included: having a standardized approach to bias
assessments; the transparency provided by requesting
quotes; the flexibility of the tool; the figures that can be
produced in RevMan (the Cochrane Collaboration’s soft-
ware for systematic reviews and meta-analyses); providing
a good framework for consideration of the risk of bias;
and providing a platform to encourage critical thinking.
Questions about these potential benefits were therefore
included in the survey. The main drawbacks described,
which were also addressed in the survey, included: the
increased workload and complexity as compared with past
practice; the subjectivity of assessments; and a lack of
clarity regarding the meaning of the ‘Yes’, ‘No’ or ‘Unclear’
judgements. The original RoB tool phrased the judge-
ments as answers to questions requiring a ‘Yes’, ‘No’ or
‘Unclear’ response, with ‘Yes’ reflecting a low risk of bias.
Many participants deemed this wording to be confusing
and instead expressed a preference for a direct response
such as ‘Low risk’. The analysis of the focus group discus-
sions identified important topics to cover in the survey
and helped formulate survey questions and possible
response options.
The focus groups also identified issues and suggestions
that would require discussion during the subsequent
face-to-face meeting relating to how the RoB tool is used
in practice. For example, several participants raised the
issue that RoB assessments present a particular problem
when updating systematic reviews. Adopting the new
tool in an updated review requires review authors to re-
assess the risk of bias of studies included in the original
review, which they were often unwilling to do, and
Cochrane Review Groups were not resourced to do this
on behalf of authors. Participants also suggested that
graphical displays of RoB assessments across studies
should be prepared separately for individual outcomes
measured in the review rather than at the study level, as
individual outcomes can be judged to be at higher or
lower risk of bias using the tool. They further suggested
that such figures should reflect the sizes of the studies
rather than a simple count of how many studies were in
each RoB judgement category, as had been implemented
in RevMan.
Finally, training and guidance materials (for example the
Cochrane Handbook guidance, workshops) were consideredimportant by focus group participants. Most participants
described these materials as clear, but editorial groups
described a challenge in persuading authors to follow and
understand the guidance. Participants also described a
need for more, in particular online, training materials. A
list of specific gaps in existing guidance was developed to
guide future training needs. These include guidance on:
how to use RoB assessments within systematic reviews;
how to assess risk of bias for study designs other than
randomized trials; and whether and when it might be
appropriate to add specific items (for example reporting
of power calculations, funding source) to the ‘other’ bias
domain. For detailed focus group findings see Additional
file 1: Appendix 4.
Survey
In total, 380 respondents completed the survey. This
represents a 4.4% response rate under assumptions that
all subscribers’ emails were active and up-to-date, and
that there was no overlap in subscribers between mailing
lists. We received 190 responses from authors who had
used the RoB tool and 132 from authors who had not
(non-users). Of the 58 Cochrane Review Group staff
who responded, 19 were managing editors, 11 coordinat-
ing editors, 11 editors and 17 other staff.
Non-users of the RoB tool were asked nine questions
covering: reasons for not using the RoB tool; training
needs; and opinions on the availability of training. Most
non-user respondents identified themselves as likely fu-
ture users, for example because: they had not conducted
a Cochrane review since the introduction of the RoB
tool (95 of the 132 respondents); their review was still in
the protocol stage (four respondents); they had not yet
started the RoB assessments for their review (three re-
spondents); or their co-authors were tasked with complet-
ing the RoB assessments (four respondents). Only eight
respondents stated that they preferred using another
assessment method, and two stated that their reason for
non-use of the tool was the time it would take to use it.
The answers of non-user respondents to training-related
questions are summarized in Table 2 and provided in
detail in Additional file 1: Appendix 2.
Authors’ and editorial staff’s experience with using the risk
of bias tool
Table 3 presents the main results from the survey of
review authors who had used the RoB tool, while Table 4
presents a summary of Cochrane Review Group staff re-
sponses to related questions, answered from an editorial
perspective. Authors of all levels of experience with the
RoB tool were represented in the survey (Table 3, Q1).
The time taken to complete a RoB assessment for one
trial varied widely among respondents, but the majority
of respondents considered the time taken to be acceptable









Training in RoB assessment (Q25, Q2, Q24)a
Attended workshop at Cochrane Colloquium 74 (39) 14 (11) 29 (50)
Attended standard Cochrane author training 44 (23) 15 (11) 6 (10)
Read relevant material in own time 124 (65) 34 (26) 37 (64)
No specific training 29 (15) 84 (64) 9 (16)
Read guidance in Cochrane Handbook related to RoB tool (Q26, Q3, Q25) 178 (94) 44 (34) 55 (95)
Read Chapter 8 of the Cochrane Handbook (Q26a, Q3a, Q25a)a 144 27 44
Read Cochrane Handbook (Part 2) from start to finish 30 14 16
Used Cochrane Handbook to look up specific issues 147 27 47
Level of detail provided in the Cochrane Handbook is appropriate (Q26b, Q3b, Q25b) 133 39 42
Provision of additional examples would be beneficial (Q26c, Q3c, Q25c) 142 39 48
Received guidance from CRG related to RoB tool (Q27, Q4) 80 (42) 20 (16) Not applicable
CRG provides guidance related to RoB tool to their authors (Q26) Not applicable Not applicable 44 (80)
Advice to read Chapter 8 of Cochrane Handbooka 43 8 41
Specific written advice developed by the CRGa 31 1 18
Specific verbal advice given by the CRGa 33 6 13
Advice provided by CRG rated good, very good or excellent (Q27b, Q4b) 67 19 Not asked
Availability of written guidance is sufficient (Q28, Q5, Q27) 139 (75) 75 (65) 36 (63)
Availability of training events is sufficient (Q29, Q6, Q28) 117 (68) 55 (50) 28 (50)
Format of training most likely to access (Q30, Q7)
Not asked
Training that is part of standard author training 32 (17) 18 (14)
Online training, including webinars 102 (55) 74 (59)
In-person workshops 51 (27) 28 (22)
Level of training most likely to access (Q31, Q8)
Not asked
Beginning 22 (12) 60 (48)
Intermediate 78 (41) 45 (36)
Advanced 89 (47) 19 (15)
Only the most frequent responses shown in the table, and some response options have been grouped to fewer categories. Not all respondents answered each
question. Question numbers refer to the survey questions in Additional file 1: Appendices 1, 2 and 3, respectively. For full details of questions and responses, see
Additional file 1: Appendices 1 to 4. a Respondents were allowed to select multiple answers for this question. CRG, Cochrane Review Group; RoB, risk of bias.
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between number of reviews authored and reported speed
of completing RoB assessments (χ2 = 18.9, P = 0.27). The
majority of respondents (159, 84%) completed the
recommended RoB table in RevMan, while 68 (36%)
also included at least one RoB figure. The majority of
respondents thought that the requirement to add
quotes added transparency (128 authors and 49 editor-
ial staff ) and increased confidence in RoB assessments
(104 authors and 30 editorial staff; see Additional file 1:
Appendices 1 and 3).
Nearly a third of respondents (56, 31%) said they had used
a modified version of the RoB tool to assess randomizedtrials (Tables 3 and 4, Q7). Modifications consisted of add-
ing new domains, modifying criteria for ‘Yes/Unclear/No’
judgements, or removing some domains. These modifi-
cations were usually based on own expertise (37 respon-
dents), or following guidelines from their Cochrane Review
Group (21 respondents; see Additional file 1: Appendix 1).
Thirty-nine (21%) respondents had used the RoB tool to
assess non-randomized studies, and 16 editorial staff
who responded (28%) stated their review group recom-
mended this practice. When used for this purpose, the
RoB tool was usually modified (Tables 3 and 4, Q6).
Non-randomized study designs identified by respondents
were quasi-randomized, cohort, case-control, cross-sectional,
Table 3 Extract of results from survey of Cochrane review authors who had used the risk of bias tool
Survey questions n (%)
Number of reviews respondent used RoB tool in (Q1)
One 80 (42)
Two or three 75 (40)
More than three 33 (18)
Used RoB tool to update an existing review (Q2) 102 (54)
Time taken to complete RoB assessment for one study (Q3)
Up to 10 minutes 23 (12)
10 to 20 minutes 81 (43)
20 minutes to 1 hour 69 (37)
More than 1 hour 14 (8)
Time taken is acceptable (Q4) 156 (83)
Used pilot testing (Q5) 62 (33)
Modified the RoB tool when used for randomized trials (Q7) 56 (31)
Used the RoB tool for non-randomized studies (Q6) 39 (21)
Modified the RoB tool when used for non-randomized studies (Q6a) 31
RoB assessments incorporated in conclusion/analysis: (Q9)a
Sensitivity analysis by RoB judgement 76 (40)
Included a narrative summary 104 (55)
Not at all 26 (14)
Used direct quotes to support judgement (Q10)
Always or nearly always 76 (41)
Often 59 (32)
Feel confident in their RoB assessments (Q12)
Very confident 61 (32)
Somewhat confident 111 (59)
Tool is better than previous Cochrane practice (Q13) 165 (87)
Features respondents most liked (Q14)a
Ability to provide information (for example quotes) 140 (74)
Standardized approach 153 (81)
Features respondents least liked (Q15)a
Judgement options (Yes/No/Unclear) confusing 69 (36)
Time taken to complete 56 (29)
Encountered problems with assessing sequence generation (Q17) 82 (44)
Encountered problems with assessing allocation concealment (Q18) 90 (50)
Encountered problems with assessing blinding (Q19) 94 (52)
Encountered problems with assessing incomplete outcome data (Q20) 122 (67)
Encountered problems with assessing selective outcome reporting (Q21) 110 (60)
Encountered problems with assessing other bias (Q22) 107 (58)
Other bias domain is helpful (Q23) 108 (61)
Use standard ‘other sources of bias’ (Q24) 53 (29)
Based on 190 respondents, authors who have used the RoB tool. Only the most frequent responses shown in the table, and some response options have been
grouped to fewer categories. Not all respondents answered each question. Question numbers refer to the survey question in Additional file 1: Appendix 1. For full
details of questions and responses, see Additional file 1: Appendix 1. a Respondents were allowed to select multiple answers for this question. RoB, risk of bias.
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Table 4 Extract of results from survey of Cochrane Review Group staff
Survey questions n (%)
Respondent’s role in the CRG (Q1)
Managing editor 19 (33)
Coordinating editor 11 (19)
Other editor 11 (19)
Trial search coordinator/information specialist 2 (3)
Other 15 (26)
CRG policy regarding RoB assessments for new reviews (Q2)
All new reviews must include RoB assessment 45 (78)
Recommended, but not compulsory 9 (16)
No clear policy or not sure 4 (7)
CRG policy regarding RoB assessments for updated reviews (Q3)
All updated reviews must include RoB assessment 28 (48)
Only for newly included studies (Q3a) 3
Both newly and previously included studies (Q3a) 10
Recommended, but not compulsory 22 (38)
Only for newly included studies (Q3a) 0
Both newly and previously included studies (Q3a) 14
No clear policy or not sure 8 (14)
CRG staff verify assessments completed by their authors (Q4) 31 (53)
CRG recommend authors use pilot testing (Q5) 20 (35)
CRG recommend a modified RoB tool for randomized studies (Q7) 13 (23)
CRG recommend authors use RoB tool for non-randomized studies (Q6) 16 (28)
CRG recommend a modified tool for non-randomized studies (Q6a) 11
CRG recommend authors incorporate RoB in conclusion by: (Q9)a
Conducting sensitivity analysis by RoB judgement 33 (57)
Including a narrative summary within interpretation of results 24 (41)
No specific recommendation 15 (26)
CRG recommend use of quotes to support RoB judgements (Q10) 34 (57)
RoB tool is better than previous Cochrane practice (Q12) 55 (95)
Features respondents most liked (Q13)a
Ability to provide information (for example quotes) 48 (83)
Standardized approach 46 (79)
Features respondents least liked (Q14)a
Judgement options (Yes/No/Unclear) confusing 24 (41)
Time taken to complete 20 (34)
Authors encounter problems with assessing sequence generation (Q16) 17 (29)
Authors encounter problems with assessing allocation concealment (Q17) 29 (50)
Authors encounter problems with assessing blinding (Q18) 33 (59)
Authors encounter problems with assessing incomplete outcome data (Q19) 41 (72)
Authors encounter problems with assessing selective outcome reporting (Q20) 38 (67)
Authors encounter problems with assessing ‘other bias’ (Q21) 32 (56)
Other bias domain is helpful (Q22) 27 (47)
CRG recommend standard ‘other sources of bias’ (Q23) 10 (17)
Based on 58 respondents, Cochrane Review Group staff. Only the most frequent responses shown in the table, and some response options have been grouped to
fewer categories. Not all respondents answered each question. Question numbers refer to the survey question in Additional file 1: Appendix 3. For full details of
questions and responses, see Additional file 1: Appendix 3. aRespondents were allowed to select multiple answers for this question. CRG, Cochrane Review Group; RoB,
risk of bias.
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studies. Modifications were usually based on respondents’
expertise and literature, but with no consistent or standard
approach. Two other instruments reported to be used for
this purpose were the Newcastle-Ottawa scale [10,11] and
the Cochrane Effective Practice and Organisation of Care
(EPOC) Group’s quality assessment checklist (see Additional
file 1: Appendices 1 and 3) [12].
The survey responses indicated that authors need
clearer guidance on what to do with RoB assessments
once completed: 26 (14%) respondents did not incorpor-
ate their RoB assessments into review conclusions at all,
while the majority (104, 55%) opted to include a narra-
tive summary (Table 3, Q9). In terms of review group
policy, the most prevalent recommendation was that au-
thors should include a sensitivity analysis (Table 4, Q9).
Issues specific to individual bias domains
Authors reported some difficulties in completing each
bias domain, but the domains thought to be most diffi-
cult were ‘incomplete outcome data’ and ‘selective out-
come reporting’ (Table 3, Q17 to Q22). Editorial staff
identified similar issues (Table 4, Q16 to Q21). Never-
theless, 172 (91%) of respondents reported feeling ‘some-
what’ or ‘very confident’ in their RoB assessments
(Table 3, Q12). We did not observe an association be-
tween the number of domains with which respondents
reported problems and whether or not they had any
RoB-specific training (T = 0.29, P = 0.77). Similarly, hav-
ing received specific RoB training was not associated
with the respondents’ level of confidence in their RoB
assessments (T = 1.59, P = 0.11). We describe below
more detailed responses for each domain (shown in
Additional file 1: Appendix 1).
The most common problems with assessing sequence
generation were: confusing sequence generation with al-
location concealment (50% of those reporting a problem
with this domain); and difficulty in assessing whether a
particular reported method was associated with bias
(52% of those reporting a problem). Respondents also
reported that the method of sequence generation was
commonly not described in trial reports and accordingly
wanted guidance on how to make judgements based on
their overall impression of trial conduct. Similarly, if al-
location concealment is well described and adequate,
respondents wanted guidance on whether this can be
used as a basis for a judgement of low risk of bias for
sequence generation. Most respondents reported that
they simply select ‘unclear’ whenever study reports do
not describe sequence generation.
The most common problems with allocation conceal-
ment were: difficulty in assessing whether a particular
reported method was associated with bias (61% of those
reporting a problem with this domain); confusingallocation concealment with blinding (34% of those
reporting a problem); and consistency between assessors
(26%). Again, a commonly raised issue was insufficient
information in the trial report, especially for older
studies.
Respondents who reported problems with blinding ex-
perienced difficulty with making a judgement in studies
where patients and/or caregivers cannot be blinded (68%
of those reporting problems), while 64% reported difficulty
in making a global assessment of blinding of patients, pro-
viders and outcome assessors.
The most common problems with the incomplete out-
come data domain included: difficulties in making an
assessment when the dropout rate is described but not
acceptable (55% of those reporting a problem); establish-
ing whether an intention-to-treat analysis had been con-
ducted (57%); establishing what constitutes ‘complete’
outcome data (67%); making assessments of missing out-
come data at different follow-up periods (52%); and con-
fusing incomplete outcome data with selective outcome
reporting (33%). Inconsistency in the meaning and under-
standing of the phrase ‘intention-to-treat analysis’ was also
cited as a source of problems in some free-text answers.
The most common problem reported for selective out-
come reporting was making an assessment without access
to a study protocol (86% of those reporting a problem)
and confusing selective outcome reporting with incom-
plete outcome data (41%). Inconsistency between asses-
sors (20%) and lack of standard outcome measures in a
given clinical area (22%) were also reported. One respond-
ent raised concerns that this domain is not relevant to
review results because either the missing information can
be obtained from the study author, or the study cannot be
included in the meta-analysis and should thus be excluded
from the RoB table.
Many respondents (95, 89% of those reporting a prob-
lem with this domain) found it difficult to decide what
should be considered under other sources of bias. Some
suggested the domain is too vague and therefore open to
misuse. The following are some of the items respondents
had included under the ‘other bias’ domain in their re-
views: compliance; baseline comparability; funding source
and conflict of interest; adjustment for confounding factors;
biases in cluster-randomized trials; carry-over effects in
cross-over trials; co-interventions; early stopping of trials
for benefit; multiple interim analyses; sample size calcula-
tions; publication bias; selection/recruitment bias; validity
of outcome measures; surgical learning curve; and timing
of outcome assessment. A decision on what should be in-
cluded in the ‘other bias’ category had usually been made
in consultation with co-authors (39 respondents).
Responses relating to training specific to the RoB tool
are shown in Table 2 for all three groups of respondents,
separately. Existing training materials and opportunities
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favour provision of additional examples and web-based
training.
Recommendations and implementation
At the face-to-face meeting in March 2010, 23 partici-
pants considered the findings of the focus groups and
the surveys and made consensus-based recommenda-
tions for improvements to the RoB tool, which are sum-
marized in Table 5. Some of the short-term changes
were implemented in a new edition of the Cochrane
Handbook [8] and RevMan version 5.1 [13]. Specifically,
wording of bias judgements was changed from ‘Yes/No/
Unclear’ to ‘Low/High/Unclear’ risk of bias; category
headings were introduced for selection, performance and
detection, attrition, reporting, and other bias; authors are
now encouraged to make separate judgements for blind-
ing for 1) participants and personnel, and 2) outcome
assessment; and guidance was clarified, particularly for
incomplete outcomes, selective outcome reporting and
‘other sources of bias’.
Medium- and longer-term recommendations (imple-
mentation to coincide with the development of RevMan
version 6 or later) include: separation of assessments of
blinding into blinding of participants and personnel
(under performance bias) and blinding of outcome assess-
ment (under detection bias) will be enforced by structural
changes in the software; weighting RoB graphs by study
size; providing an algorithm for reaching a summaryTable 5 Summary of the panel recommendations and their im
Recommendations Im
Change the wording of bias judgements from ‘Yes/No/Unclear’ to
‘Low/High/Unclear risk of bias’
Im
Introduce category headings for selection, performance and detection,
attrition, reporting, and other bias
Im





Clarify guidance, particularly for incomplete outcomes and selective
outcome reporting, and ‘other sources of bias’
G
de
Produce clearer and more explicit guidance on incorporation of RoB
assessments into meta-analyses
Fu
Weight RoB graphs by study size Sc





Develop online guidance and training materials including an online
frequently asked questions and a bank of worked examples of
assessments
W
Assess how frequently Cochrane Review Groups include
non-randomized studies in their reviews
Su
no
Develop a RoB tool for the assessment of non-randomized studies Th
M
RoB, risk of bias.assessment of risk of bias per study/outcome; and
developing a RoB tool for assessment of non-randomized
studies. Extensions to the written guidance will be
incorporated into upcoming versions of the Cochrane
Handbook, including: further clarification of guidance with
regards to selective reporting and other sources of bias;
clearer and more explicit guidance for incorporating RoB
assessments into meta-analyses; an algorithm for formu-
lating summary assessments across domains of bias; and a
bank of worked examples. A dedicated steering group was
formed in 2011, funded by the Cochrane Collaboration’s
Methods Innovation Fund, to develop a RoB tool for the
assessment of non-randomized studies. This work is ex-
pected to be completed by the end of 2014. Another
working group, formed in 2012, was tasked with introdu-
cing signalling questions within each bias domain and an
overall RoB judgement for each outcome in the RoB tool
for randomized trials in order to provide a more struc-
tured framework for reaching domain-level and outcome-
level judgements. The same structure of signalling ques-
tions and bias domains is being implemented in RoB tools
for randomized and non-randomized studies, with the
aim of applying the same standards of assessments for all
study types.
Discussion
Our multi-staged evaluation of the RoB tool found wide
acceptance of the need for the tool, with consensus that
it represents an improvement over methods previouslyplementation to date
plementation of recommendations
plemented in RevMan version 5.1 and Cochrane Handbook version 5.1.0
plemented in RevMan version 5.1 and Cochrane Handbook version 5.1.0
plemented partially in RevMan version 5.1 and Cochrane Handbook
rsion 5.1.0. Full structural implementation scheduled for RevMan
rsion 6
uidance improved in Cochrane Handbook version 5.1.0. Further guidance
velopment ongoing
rther guidance development ongoing
heduled for RevMan version 6
orking group established in 2012 to develop RoB tool 2.0 with signalling
estions introduced into the tool to help guide assessors to make a
main-based judgement in a more structured way
orking group tasked with the development of RoB tool 2.0
rvey completed in 2012 as part of the development of the RoB tool for
n-randomized studies
e development of the RoB tool for non-randomized studies started in
arch 2012 and is expected to finish by the end of 2014
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pretation of these findings should however be cautious,
due to a low response rate of the survey. The time re-
quired to complete assessments of risk of bias was
greater than had been required by previous approaches,
but was nonetheless considered acceptable. A high pro-
portion of respondents reported problems with each of
the individual RoB domains. The domains reported to
be the most difficult to assess were risk of bias due to in-
complete outcome data and selective reporting of out-
comes. There was wide variation in how review authors
had approached the ‘other bias’ domain, with a lack of
clarity over what additional items should be considered
here. Some of the items that authors have included (such
as sample size calculations and funding source) are ex-
plicitly discouraged in the Cochrane Handbook guidance.
While there is evidence that some factors are empirically
associated with effect estimates, such as single versus
multicentre design, early stopping of trials and funding
source [14-16], the extent to which these should be con-
sidered alongside the main bias domains is still a topic
of debate.
The evaluation highlighted a need for more and better
training and guidance materials, such as algorithms or
similar structured guidance for reaching domain-level
judgements, as well as guidance on how to incorporate
RoB assessments into meta-analyses and review conclu-
sions. Recommendations for changes or further develop-
ments were made based on identified needs and many
have already been incorporated into the new edition of
the Cochrane Handbook, while other developments are
underway. As suggested by evaluation participants, an
online bank of worked examples for RoB assessments
will be incorporated into future versions of the Cochrane
Handbook or made available online.
This was the first study to evaluate the implementa-
tion of the new Cochrane tool for assessment of trials
included in reviews. We used qualitative methods (focus
groups) to help design the questionnaire, which we
piloted to improve face validity. The focus groups were
facilitated by the authors (DM, JACS, JS or LW), two of
whom are bias experts and contributed to the develop-
ment of the original RoB tool (DM and JACS). It is
possible that, under such circumstances, the participants
could have been reluctant to admit lack of understand-
ing or confusion with the tool. However, the main pur-
pose of the focus groups was to inform the development
of the survey questionnaire and not to draw any firm
conclusions. Some of the focus group participants were
later involved in the piloting of the questionnaire. Al-
though the proportion of respondents to the survey was
small (4.4% of the 7,368 mailing list subscribers), it is
possible that the effective response rate was somewhat
higher due to a combination of overlap among the fourmailing lists and the presence of inactive Cochrane re-
view authors on the authors’ list. However, given the low
response rate, it is possible that authors and Cochrane
Review Group staff who read the email and chose to
respond differ from those who did not read the email or
chose not (or forgot) to respond. Due to time limita-
tions, our survey was live for only 3 weeks, which also
could have reduced the response rate. Nevertheless, the
main purpose of this evaluation was to identify potential
problems with the RoB tool that can be rectified, and we
suspect that users who encountered problems are more
likely to have responded. This speculation is based on
the high proportion of respondents who reported having
problems with some aspects of the RoB tool, especially
with individual RoB domains. However, it is equally pos-
sible that those users of the RoB tool who experienced the
most problems with RoB felt disillusioned and chose not
to participate. One further limitation to consider is that
the survey measured confidence and self-reported diffi-
culty; it is possible that the number of people incorrectly
applying these concepts may be higher as authors may be
unaware of their misunderstandings. We also wanted to
gauge general perceptions of users of the RoB tool, and to
find out if their training needs were being met. Another
potential limitation is the small number of non-users of
the RoB tool represented in the evaluation. It is impossible
to determine whether the number of non-user respon-
dents was small because few authors made a decision not
to use the tool or because such authors chose not to
respond to the survey.
We are not aware of a similar survey of Cochrane re-
view authors or evaluation of the RoB tool. Several stud-
ies used other methods to investigate the use of the RoB
tool in practice and evaluate its reliability. Hartling et al.
found that, although the tool takes longer to complete
than other approaches, trials assessed to be at high risk
of bias produced more exaggerated effect estimates com-
pared to low risk trial reports [17]. This is consistent
with other empirical studies [2,18]. The same authors
assessed the reliability of the tool and found, consistent
with the results reported here, that incomplete outcome
data and selective reporting are the most difficult do-
mains to assess [17]. It is important that guidance and
training materials continue to be developed for all as-
pects of the tool, but particularly these two items. One
of the findings from our evaluation that was of particular
concern is that 44% or more of respondents had diffi-
culty with assessing each of the individual RoB domains.
This is consistent with the results of the reliability test-
ing reported by Hartling et al. [17]. Inter-rater reliability
is a substantial problem facing the RoB tool, in common
with many of the other tools used for similar purposes
in systematic reviews. Nevertheless, a further study has
found the reliability of the RoB tool to be better when
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ment on bias domains ranging from fair to almost per-
fect [19]. Liu et al. carried out a review of systematic
reviews of acupuncture in Chinese journals in the period
from 2009 to 2011 in order to assess the prevalence of
use of the Cochrane RoB tool in this field of research.
They found that only 6% of reviews reported informa-
tion on all six RoB domains [20].
Our evaluation led to recommendations for improve-
ments to the tool [9]. There was consensus that assess-
ment of blinding should be separated into blinding of
participants and health professionals (performance bias)
and blinding of outcome assessors (detection bias), and
that classification of bias domains into categories of bias
(selection bias, performance bias, detection bias, attrition
bias, reporting bias and other bias) would be helpful.
Some of the recommended changes have been imple-
mented in RevMan version 5.1 [13] and in a revised ver-
sion of the Cochrane Handbook, released in March 2011
[8]. There was agreement that improved training materials
and availability of worked examples would increase the
quality and reliability and reduce misuse of items assessed
in RoB assessments.
The current RoB tool addresses main sources of bias
in randomized trials of a standard parallel-group design.
The evaluation helped to identify a need for timely de-
velopment of extensions of the RoB tool to cover other
randomized trial designs, and non-randomized studies.
The next generation of the tool will meet the need for
more structured guidelines for reaching domain-based
RoB judgements (for example algorithms), since it will
introduce a signalling question-based approach as used
in the QUADAS 2 tool for assessing diagnostic accuracy
studies [21]. Signalling questions are additional, specific
questions within each bias domain aimed at helping the
assessor reach the domain-level judgement more easily
and in a more structured way.
More empirical evidence is needed to further inform con-
siderations of what methodological aspects are most im-
portant in assessing risk of bias. There is a particular need
for assessment of the influence of participant attrition on
effect estimates, and on separate contributions to bias from
blinding of patients and caregivers versus blinding of out-
come assessors. Further, clearer guidance, ideally based on
empirical evidence, is needed on how to deal with studies
at high risk of bias in meta-analyses, other syntheses of evi-
dence across studies and drawing conclusions.
Conclusion
Our evaluation of the Cochrane RoB tool suggests that it
is a step in the right direction, but that revisions of the tool
and associated guidance, and improved provision of train-
ing, are required. Extensions of the tool for non-parallel
group randomized trials and non-randomized studies wereidentified as a priority and such developments have been
initiated as a consequence of this evaluation.
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